Ozanimod (RPC1063) - 98%, high purity , CAS No.1306760-87-1, Agonist of S1P 1 receptor;Agonist of S1P 2 receptor;Agonist of S1P 3 receptor;Agonist of S1P 4 receptor;Agonist of S1P 5 receptor

Item Number

O413886

• Synonyms: HY-12288 | 5-[3-[(1~{S})-1-(2-hydroxyethylamino)-2,3-dihydro-1~{H}-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxy-benzenecarbonitrile | D10968 | DTXSID501026488 | Ozanimod [USAN:INN] | RPC1063:RPC-1063 | DB12612 | L04AA38 | AMY3373 | EX-A1316 | 5-{3-[
• Specifications & Purity: Moligand™, ≥98%
• Biochemical and Physiological Mechanisms: Ozanimod (RPC1063) is a selective oral S1P Receptor 1 modulator. Phase 3.
• Storage Temp: Store at -20°C
• Shipped In: Ice chest + Ice pads
• Grade: Moligand™
• Action Type: AGONIST
• Mechanism of action: Agonist of S1P 1 receptor;Agonist of S1P 2 receptor;Agonist of S1P 3 receptor;Agonist of S1P 4 receptor;Agonist of S1P 5 receptor

Product Description

Information

Ozanimod (RPC1063) Ozanimod (RPC1063) is a selective oral S1P Receptor 1 modulator. Phase 3.

Targets

S1P1R (Cell-free assay); S1P5R (Cell-free assay) 0.41 nM(EC50); 11 nM(EC50)

In vitro

In S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R internalization and degradation.

In vivo

Ozanimod shows high oral bioavailability and volume of distribution. In a MOG-induced EAE mouse model, Ozanimod (3 mg/kg, p.o.) suppresses clinical symptoms. In a rat TNBS model of inflammatory bowel disease, Ozanimod (1.2 mg/kg, p.o.) inhibits clinical and histological disease scores. In a Naïve CD4+CD45Rbhi T cell adoptive transfer model, Ozanimod (1.2 mg/kg, p.o.) also significantly reduced disease severity as assessed by measuring the degree of inflammation, gland loss, hyperplasia, neutrophil infiltrate and mucosal thickness.